UPyTher Secures $2.8 Million in Seed Funding to Revolutionize Peritoneal Oncology Treatment

UPyTher, a pioneering spin-off company from the Eindhoven University of Technology, is thrilled to announce a successful funding round that has raised €2,800,000 in investment. Founded in 2020, UPyTher is at the forefront of revolutionizing treatment for peritoneal diseases, particularly peritoneal carcinomatosis, which demands innovative approaches to local drug delivery. With a firm belief in the potential of long-acting hydrogel-drug formulations, the company aims to enhance treatment options and outcomes for patients facing this challenging condition. The funding will be instrumental in advancing UPyTher's preclinical work, enabling further development and optimization of their unique hydrogel formulations, which are specifically designed for intraperitoneal therapy. By creating therapies that are not only effective but also simple and safe to administer, UPyTher is poised to set a new standard of care in the field of peritoneal oncology. The investment will also support the company in conducting essential studies to validate the efficacy and safety of its treatments. UPyTher's ultimate vision is to transform peritoneal carcinomatosis into a manageable disease, fundamentally improving the quality of life for patients. With the new funding, UPyTher is excited to embark on the next phase of its journey, aiming to bring groundbreaking solutions to patients in need and contribute significantly to the evolution of treatment methods in oncology.